Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: A case report

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Seo, Yu Ri ^a   Kim, Se Hyung ^a   Kim, Hyun Jung ^a   Kim, Chan Kyu ^a   Park, Seong Kyu ^a   Koh, Eun Suk ^b   Hong, Dae Sik ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; FOLFOX PROTOCOL; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; CASE REPORT; COLON CANCER; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; TRANSITIONAL CELL CARCINOMA; TRANSTHORACIC BIOPSY; TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL TRACT CANCER; CANCER INVASION; DISEASE COURSE; DRUG EFFECT; LUNG TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REMISSION; URINARY TRACT CANCER; UROTHELIUM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FLUOROURACIL; HUMANS; LEUCOVORIN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; ORGANOPLATINUM COMPOUNDS; REMISSION INDUCTION; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 76749137280     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-4     Document Type: Article

References (23)

1. EAU Guidelines on Diagnosis and Treatment of Upper Urinary Tract Transitional Cell Carcinoma. W Oosterlinck E Solsona APM van der Meijden R Sylvester A Böhle E Rintala B Lobel, European Urology 2004 46 147 154 10.1016/j.eururo.2004.04.011 15245806
2. Methotrexate, vinblastine, doxorubicin, and cisplatin for Advanced Transitional Cell Carcinoma of the Urothelium. Efficacy and patterns of response and relapse. CN Sternberg A Yagoda HI Scher, Cancer 1989 64 2448 2458 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7 2819654
3. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. WG Harker FJ Meyers FS Freiha JM Palmer LD Shortliffe JF Hannigan KM McWhirter FM Torti, J Clin Oncol 1985 3 1463 1470 4056840
4. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). BJ Roth DF Bajorin, world J Urol 1995 153 894 900
5. H von der Maase SW Hansen JT Roberts L Dogliotti T Oliver MJ Moore I Bodrogi P Albers A Knuth CM Lippert P Kerbrat P Sanchez Rovira P Wersall SP Cleall DF Roychowdhury I Tomlin CM Visseren-Grul PF Conte, J Clin Oncol 2000 18 3068 3077 11001674
6. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. V Lorusso CF Pollera M Antimi G Luporini C Gridelli GL Frassineti C Oliva M Pacini M De Lena, Eur J Cancer 1998 34 1208 1212 10.1016/S0959-8049(98)00030-6 9849481
7. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. MJ Moore IF Tannock DS Ernst S Huan N Murray, J Clin Oncol 1997 12 3441 3445
8. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. P D Dodd M Bajorin M Mazumdar M Fazzari J A McCaffrey H I Scher H Herr G Higgins M G Boyle, J Clin Oncol 1999 17 3173 3181 10506615
9. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. J Bellmunt J Albanell L Paz-Ares MA Climent JL Gonzalez-Larriba J Carles JJ de la Cruz V Guillem E Diaz-Rubio H Cortes-Funes J Baselga, Cancer 2002 95 751 757 10.1002/cncr.10762 12209718
10. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. J Carles E Esteban M Climent A Font JL Gonzalez-Larriba A Berrocal I Garcia-Ribas X Marfa X Fabregat J Albanell J Bellmunt, Annals of Oncology 2007 18 1359 1362 10.1093/annonc/mdm160 17693649
11. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. TA Dunn HJ Schmoll V Granwald V Bokemeyer J Casper, Invest New Drugs 1997 15 109 114 10.1023/A:1005800520747 9220289
12. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. O Rixe W Ortuzar M Alvarez R Parker E Reed K Paull T Fojo, Biochem Pharmacol 1996 52 1855 1865 10.1016/S0006-2952(97)81490-6 8951344
13. Phase II study of oxaliplatin in patients with inoperable, locally advanced or metastatic transitional cell carcinoma of the urothelial tract (TCC) who have received prior chemotherapy. MJ Moore E Winquist E Vokes H Hirte K Hoving WM Stadler, Proc Am Soc Clin Oncol 2003 22 48 52
14. A Phase II study of oxaliplatin in urothelial cancer. E Winquist E Vokes MJ Moore LP Schumm K Hoving WM Stadler, Urologic Oncology: Seminars and Original Investigations 2005 23 150 154
15. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. S Giacchetti B Perpoint R Zidani N Le Bail R Faggiuolo C Focan P Chollet JF Llory Y Letourneau B Coudert F Bertheaut-Cvitkovic D Larregain-Fournier A Le Rol S Walter R Adam JL Misset F Levi, J Clin Oncol 2000 18 136 147 10623704
16. Superiority of oxaliplatin and 5-FU/leucovorin over either therapy alone in patients with progressive colorectal cancer following irinotecan and 5-FU/leucovorin: interim results of a phase III trial. ML Rothenberg AM Oza RH Bigelow JD Berlin JL Marshall RK Ramanathan LL Hart S Gupta CA Garay BG Burger N Le Bail DG Haller, J Clin Oncol 2003 21 2059 2069 10.1200/JCO.2003.11.126 12775730
17. Chemotherapy of urothelial tract tumors. A Yagoda, Cancer 1987 60 574 585 10.1002/1097-0142(19870801)60:3+<574::AID-CNCR2820601524>3.0.CO;2-C 3297286
18. Fluorouracil and recombinant human interferon alpha-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. CJ Logothetis E Hossan A Sella FH Dexeus RJ Amato, J Natl Cancer Inst 1991 83 285 288 10.1093/jnci/83.4.285 1994058
19. A Phase II Trial of Continuous 5-Fluorouracil in Recurrent or Metastatic Transitional Cell Carcinoma of the Urinary Tract. MS Highley GO Griffithsy BM Uscinskay JB Huddartz P Barberx MKB Parmary PG Harper, Clinical Oncology 2009 21 394 400 10.1016/j.clon.2009.01.011 19269798
20. th annual meeting of the American Society of Clinical Oncology. M Javle CT Hsueh, Journal of Hematology & Oncology 2009 2 9
21. Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. N Malavasi G Ponti R Depenni F Bertolini S Zironi G Luppi PF Conte, Journal of Hematology & Oncology 2009 2
22. FOLFOX-4 in Pre-treated Patients with Advanced Transitional Cell Carcinoma of the Bladder. GD Lorenzo R Autorino A Giordano M Giuliano M D'Armiento AR Bianco1 S De Placido, Jpn J Clin Oncol 2004 34 747 750 10.1093/jjco/hyh132 15640506
23. New agents for treatment of advanced transitional cell carcinoma. FGE Perabo SC Müller, Annals of Oncology 2007 18 835 843 10.1093/annonc/mdl331 17018703